The next-generation ultrasound system reportedly offers enhanced images through graphic-based beamforming technology, a variety of artificial intelligence (AI)-powered tools and reduced exam times.
Expanding upon its women’s health portfolio, GE Healthcare has launched the Voluson Expert 22 ultrasound system.
Providing enhanced imaging capabilities through the device’s Lyric Architecture, the Voluson Expert 22 ultrasound system accommodates a variety of body sizes, according to the company. Combining new levels of penetration and frame rates, GE Healthcare said the new system provides enhanced anatomical detail on a 23.8 inch high-definition ultrasound display with increased contrast and spatial resolution.
“The Voluson Expert 22 is a masterpiece of engineering with exceptional 2D images from thin to difficult scanning patients. This machine also has the outstanding ergonomics and is the most customizable system ever produced, It is one of the best ultrasound machines I have ever used,” noted Rabih Chaoui, M.D., the managing director at the Center for Prenatal Diagnosis and Human Genetics in Berlin, Germany.
In addition to a user interface that allows personalized preferences and automated probe presets, the Voluson Expert 22 offers a variety of artificial intelligence (AI)-enabled tools. GE Healthcare noted that SonoLyst provides annotations and measurements that improve the efficiency of viewing fetal anatomy by up to 65 percent. Facilitating consistent measurements and enhanced alignment of 3D views of the fetal brain, the SonoCNS feature reportedly reduces exam time by 81 percent, according to the company.
“By using AI, we are pushing limits and enhancing diagnostic capabilities. At the same time, the functionality makes exams easier. The AI built into this machine is so far advanced compared to what we’ve seen before, and it’s only a hint. It’s our responsibility to push it even further by using it, challenging it, and showing it makes a difference,” said Lawrence Platt, M.D., an obstetrician-gynecologist at the Center for Fetal Medicine in Los Angeles.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
2 Commerce Drive
Cranbury, NJ 08512